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Abstract
Background: Despite a significant number of studies on female fertility following childhood, adolescent, and young adult
(CAYA) cancer, studies establishing precise (dose-related) estimates of treatment-related risks are still scarce. Previous studies
have been underpowered, did not include detailed treatment information, or were based on self-report only without any hormonal
assessments. More precise assessments of who is at risk for sub- or infertility are needed.
Objective: The objective of our study is to describe the design and methods of 2 studies on female fertility (a cohort study and
a nested case-control study) among female survivors of CAYA cancer performed within the European PanCareLIFE project.
Methods: For the cohort study, which aims to evaluate the overall risk of fertility impairment, as well as the risk for specific
subgroups of female CAYA cancer survivors, 13 institutions from 9 countries provide data on fertility impairment. Survivors are
defined as being fertility impaired if they meet at least one of 8 different criteria based on self-reported and hormonal data. For
the nested case-control study, which aims to identify specific treatment-related risk factors associated with fertility impairment
in addition to possible dose-response relationships, cases (fertility impaired survivors) are selected from the cohort study and
matched to controls (survivors without fertility impairment) on a 1:2 basis.
Results: Of the 10,964 survivors invited for the cohort study, data are available from 6619 survivors, either questionnaire-based
only (n=4979), hormonal-based only (n=72), or both (n=1568). For the nested case-control study, a total of 450 cases and 882
controls are identified.
Conclusions: Results of both PanCareLIFE fertility studies will provide detailed insight into the risk of fertility impairment
following CAYA cancer and diagnostic- or treatment-related factors associated with an increased risk. This will help clinicians
to adequately counsel both girls and young women, who are about to start anticancer treatment, as well as adult female CAYA
cancer survivors, concerning future parenthood and to timely refer them for fertility preservation. Ultimately, we aim to empower
patients and survivors and improve their quality of life.
Registered Report Identifier: RR1-10.2196/10824
(JMIR Res Protoc 2018;7(9):e10824)   doi:10.2196/10824
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Introduction
Advances in diagnosis and treatment of childhood cancer have
led to major improvements in 10-year survival rate, which now
exceeds 80% [1]. As a consequence, the number of childhood
cancer survivors has substantially increased and many of them
have reached an age at which they consider parenthood.
However, compromised reproductive function is an important
and frequently encountered late effect of treatment in female
cancer survivors with a high impact on quality of life [2-4].
Alkylating chemotherapy and radiotherapy involving the ovaries
have been identified as the 2 main risk factors for fertility
impairment, and postpubertal treatment seems to be more
gonadotoxic than prepubertal treatment [5,6]. In addition, cranial
radiotherapy may also impair fertility, and a possible role for
nonalkylating agents must be considered [7].
Despite a significant number of studies on female fertility
following childhood and adolescent cancer, studies establishing
precise (dose-related) estimates of treatment-related risks are
scarce. Previous studies have been underpowered [6,8,9], did
not include detailed treatment information [10], or were based
on self-report only without any clinical validation [11,12]. In
addition, the different methods used to assess fertility
(questionnaires, hormonal markers, and ultrasound
measurements of the reproductive organs [13,14]), make it
difficult to compare studies. More precise assessments of who
is at risk, either for immediate and persistent infertility or a
shorter-than-anticipated reproductive window, are essential to
prevent involuntary childlessness, secondary infertility (ie,
incomplete family planning), and increased use of artificial
reproductive techniques [15]. Assessments should include both
established and relatively new clinical markers, for example,
evaluation of menstrual and pregnancy history or levels of
follicle stimulating hormone (FSH) and anti-Müllerian hormone
(AMH). Moreover, large childhood cancer survivor cohorts
with detailed treatment and long-term follow-up data on fertility
outcomes are needed to disentangle specific treatment-related
fertility risks.
We, therefore, initiated the PanCareLIFE project. This
pan-European project, originating from the PanCare network,
is a European Union funded project (7th Framework Programme,
Theme Health), coordinated by the University Medical Center
Mainz (Germany), in which investigators from 10 countries
provide data from over 15,000 CAYA cancer survivors [16].
The project is divided into 8 work packages (WP1-WP8), each
with distinct activities, and addresses 3 research topics
(ototoxicity, fertility, and quality of life). PanCareLIFE strives
for survivors of childhood, adolescent, and young adult (CAYA)
cancer to enjoy the same quality of life and opportunities as
their peers who have not had cancer. The aim of this study is
to describe the design, methods, and participating cohorts of 2
PanCareLIFE studies in WP3 (led by Amsterdam UMC, Vrije
Universiteit, AUMC) on female fertility, a cohort study and a
nested case-control study.
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Methods
The PanCareLIFE Female Fertility Cohort Study
The aim of the female fertility cohort study is to evaluate the
overall prevalence of fertility impairment among female CAYA
cancer survivors who are at least 5 years past diagnosis and
alive at the time of study assessment. Moreover, it aims to assess
the prevalence of fertility impairment for specific subgroups of
female CAYA cancer survivors based on cancer diagnosis, type
of treatment (simple, yes or no, information on chemotherapy,
radiotherapy, and surgery), age at treatment, and calendar period
of treatment.
In total, 13 institutions from 9 countries (Germany, Czech
Republic, Netherlands, Italy, Switzerland, France, United
Kingdom, Norway, and Israel) collect cross-sectional data for
the PanCareLIFE female fertility cohort study. These
institutions, referred to as data providers, provide data from 16
different institutional cohorts in total. Two of these cohorts are
registry-based cohorts (VIVE cohort and the Swiss Childhood
Cancer Survivor Study cohort), whereas all other cohorts are
hospital-based. Some of these data providers have previously
collected their data as part of a local fertility study [3,8,17-21],
whereas other data providers collect their data specifically during
the PanCareLIFE project. All survivors included in the
PanCareLIFE female fertility cohort study were treated between
1963 and 2014. However, each of the 16 cohorts encompasses
a specific time period of treatment, as identified by the data
providers. In addition, although most cohorts included all types
of cancer diagnoses, some cohorts only included survivors who
were diagnosed with a specific type of cancer (Table 1; see
Multimedia Appendix 1 for an expanded version).
Study Population
The eligibility criteria for the female fertility cohort study as
well as the different survivor groups identified based on
eligibility and type of response are described in Figure 1. The
base cohort includes all survivors meeting the inclusion criteria.
Survivors who subsequently meet one of the exclusion criteria
are deemed ineligible and are not invited for the study (excluded
subjects). All remaining women have either been invited to
participate in a local fertility study in the past or are specifically
invited to participate in the PanCareLIFE female fertility study
(invited subjects).
Those who do not respond to the invitation as well as those who
actively refuse to participate are categorized as nonparticipants.
Participants are defined as those who agree to participate by
providing either questionnaire data only, hormonal data only,
or both. All local ethical committees have approved the use of
the collected data from their institute for the PanCareLIFE
project.
Data Collection
For all women in the base cohort demographic, diagnostic and
treatment-related data are collected from medical record files
and registries. Basic demographic data include month and year
of birth and of latest follow-up. Diagnostic data include type of
diagnosis (based on the 3rd version of the International
Classification of Childhood Cancer) [22] and month and year
of diagnosis. Treatment-related data comprise surgery (yes or
no), chemotherapy (yes or no), radiotherapy (yes or no), and
bone marrow transplantation (yes or no) complemented with
the starting month and year of each treatment. Diagnostic and
treatment data are collected for all malignancies and possible
relapses.
Data on fertility impairment are collected by questionnaire and
hormonal assessments. A specific PanCareLIFE fertility
questionnaire is developed for those data providers who collect
questionnaire data on fertility issues during the PanCareLIFE
project. This questionnaire evaluates sociodemographic and
menstrual cycle characteristics, menopausal status, use of oral
contraceptives and hormones, reproductive history, and smoking
and alcohol behaviors. The questionnaire is translated from the
original English into German, Czech, Italian, and Hebrew. All
translated questionnaires are back-translated into English (by
another translator) to check if the translation is performed
properly.
Questionnaire data from questionnaires used by data providers
for previous local fertility studies address fertility issues using
different questions at different levels of detail and with different
answer categories. Therefore, a specific task for WP3
investigators is to recode the relevant data from these
questionnaires for compatibility with the variables used in the
PanCareLIFE fertility questionnaire in close collaboration with
the relevant data provider to make them as compatible as
possible.
Hormonal measurements primarily involve the assessment of
AMH levels. Study participants are asked to provide a blood
sample during a clinic visit (which takes place either as part of
standard follow-up care or is specifically scheduled for the
study). Part of the sample is centrifuged and stored at −20°C.
Subsequently, serum samples are transported in batches by
courier to AUMC, where AMH levels are determined centrally
in the endocrine laboratory. An ultrasensitive Elecsys AMH
assay is used (Roche Diagnostics GmbH, Mannheim, Germany)
with an intraassay coefficient of variation of 0.5%-1.8%, a limit
of detection of 0.01 µg/L, and a limit of quantitation of 0.03
µg/L [23]. FSH levels are accepted if they have been measured
within the previous 2 years or during standard patient care
throughout the course of the PanCareLIFE project. FSH
measurements are done locally and the results are sent to
AUMC. Specifics about the timing of blood sampling, that is,
during a natural menstrual cycle, during hormonal contraceptive
therapy or hormone replacement therapy, during the pill-free
interval, performed anytime (no cycle), during pregnancy, or
unknown, are provided.
Data providers collect all data from their own survivor cohort,
enter them into a local study database (under a unique
PanCareLIFE-ID number), anonymize the data, check the quality
of the data, and then send the data to the coordinating
PanCareLIFE data center in Mainz. In this center, all subjects
are assigned a new unique identification number. Subsequently,
the data are compiled and sent to the WP3 investigators at
AUMC, as seen in Multimedia Appendix 2.
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Table 1. Characteristics of cohorts included in the cohort study and the nested case-control study.
Time period of
data collection
Serum samples
provided
(N=1640), n
Questionnaires
provided
(N=6547), n
Women invited (n=10,964)
of total base cohorta
(N=14,379), n/N
DataStudy cohortData provider or institute
2004-201461911091684/2190PRdDCOG LATER cohortc
[17]
DCOG LATER (Amsterdam
UMC, Erasmus Medical Cen-
ter Rotterdam)b, Netherlands
1997-20160203275/450PRHodgkin Lymphoma co-
hort [19,21]
Netherlands Cancer Institute
Amsterdam, Netherlands
2014-2015024824467/5909PRVIVE cohortcUniversitätsklinikum Bonn,
Germany
2015-20162446140/161DUeEwing 2008 Clinical Trials
cohort
Westfaelische Wilhelms-Uni-
versitaet Muensterb, Germany
2008-20096983344/402PRBerlin Hormone Analyses
cohortc [3]
Charité - Universitätsmedizin
Berlin, Germany
2015-2016180182203/283DUCohort female 5-yr cancer
survivors Brnoc
Fakultni nemocnice Brnob,
Czech Republic
2014-20163015741063/1398DUCohort female 5-yr cancer
survivors Motolc
Fakultni nemocnice v Motolb,
Czech Republic
2015-2016122563814/1111DUGaslini female survivors
cohortc
Istituto Giannina Gaslinib,
Italy
2007-20130685977/1135PRSwiss Childhood Cancer
Survivor Study cohort 1c
[18]
University of Bern, Switzer-
land
2015-20160113228/335PRSwiss Childhood Cancer
Survivor Study cohort 2c
[18]
University of Bern, Switzer-
land
2015-2016445093/95DUHematopoietic stem cell
transplantation cohortc
Great Ormond Street Chil-
dren’s Hospital/University
College London Hospitalc,
United Kingdom
2007-2009465182/UnknownPRLymphoma survivor co-
hort [8]
Oslo University Hospitalb,
Norway
2009-20106582103/175PRAcute lymphoblastic
leukaemia survivor cohort
[21]
Oslo University Hospitalb,
Norway
2005-201335120120/212PRRhone Alpe cohort 1cUniversity hospital Saint-Éti-
enneb, France
2015-201662102220/284PRRhone Alpe cohort 2cUniversity hospital Saint-Éti-
enneb, France
2015-201673102151/239DUThe Edmond and Lily
Safra Children's Hospital
Late Effects cohortc
Edmond and Lily Safra Chil-
dren's Hospital, Sheba Medi-
cal Centerb, Israel
aBase cohort is the subjects fulfilling inclusion criteria of study.
bInstitutes participating in the nested case-control study.
cVarious cancer diagnoses.
dPR: data collected prior to PanCareLIFE project.
eDU: data collected during PanCareLIFE project.
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Figure 1. Flow chart of eligible, invited, and participating subjects of the 2 fertility studies within the PanCareLIFE project.
Definition of Primary Outcome
The primary outcome of the cohort study is fertility impairment.
However, given the fact that the fertility data come from
different sources, it is difficult to apply one standardized
outcome definition of fertility impairment to all participating
cohorts in the cohort study. Therefore, fertility impairment is
defined according to 8 criteria based on self-reported and
hormonal data (criteria 1, 2, and 6), hormonal data only
(criterion 3), or on self-reported data only (criteria 4, 5, 7, and
8). These criteria were established by WP3 with a reproductive
specialist (C.B. Lambalk). A survivor is classified as being
fertility impaired if she meets at least one of the 8 criteria, as
described in Textbox 1.
Low AMH is defined as an AMH level <0.5 µg/L [24]. For
criteria 1 through 3, AMH is used to validate self-reported
amenorrhea (criteria 1 and 2) or a high FSH level (criterion 3).
When AMH levels are used for such validation purposes, levels
obtained from serum samples drawn from a participant using
any type of hormones are included. However, if only AMH
levels are used to decide whether a survivor is fertility impaired
or not, like in criterion 6, levels obtained from serum samples
drawn during hormonal use are excluded. This is done because
previous reports, although inconclusive, have shown that use
of contraceptive hormones may significantly decrease AMH
levels [25,26]. FSH levels are considered high when they are
>30 U/L in a serum sample drawn during the midcycle peak
(cycle day 12-16), >15 U/L in a sample drawn at any other
moment during the menstrual cycle in case of amenorrhea, or
if the survivor uses hormones at time of serum sampling [27].
When there is no information on the timing of the serum
sampling, FSH levels are considered high if they are >30 U/L.
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Textbox 1. Criteria used to define fertility impairment.
• Criterion 1: Primary amenorrhea (never had menses) in combination with a high follicle stimulating hormone (FSH) and/or a low anti-Müllerian
hormone (AMH) level.
• Criterion 2: Secondary amenorrhea (no menses for >12 months before the age of 40) in combination with a high FSH and/or a low AMH level.
• Criterion 3: High FSH level in combination with a low AMH level, while being <40 years of age at time of study assessment.
• Criterion 4: Primary amenorrhea (without information on AMH or FSH level).
• Criterion 5: Secondary amenorrhea (without information on AMH or FSH level).
• Criterion 6: Low AMH level and <30 years of age at time of study assessment and not using exogenous reproductive hormones at time of blood
sampling.
• Criterion 7: Use of artificial reproductive techniques (excluding those who reported male factor as the single cause of subfertility) and being <40
years of age at time of study assessment.
• Criterion 8: Tried to conceive for at least 12 consecutive months without success and being <40 years of age at time of study assessment.
Planned Data Analyses
The overall prevalence of fertility impairment will be defined
as the number of participating survivors who are fertility
impaired divided by the total number of participating survivors.
The prevalence of fertility impairment will also be calculated
for subgroups based on cancer diagnosis, type of treatment
(chemotherapy, +/− surgery; radiotherapy, +/− surgery; both
chemo- and radiotherapy, +/− surgery; and surgery only), age
group at treatment, and calendar period at treatment. In addition,
the prevalence of fertility impairment according to each of the
different criteria will be calculated along with that of fertility
impairment based on the criteria that evaluate ovarian function
(criteria 1 to 6) and possible difficulties getting pregnant (criteria
7 and 8).
Multivariable logistic regression analysis will be used to
investigate which diagnostic- or treatment-related risk factors
influence the probability of being fertility impaired. All analyses
will be adjusted for possible confounders, such as age at the
time of study assessment, time since diagnosis, smoking status,
BMI, and use of hormonal contraception. Furthermore, to detect
possible selection bias, descriptive statistics will be used to
describe any differences in age at time of study assessment, age
at diagnosis, cancer diagnosis, time since diagnosis, and type
of treatment between participants, nonparticipants, and excluded
women, as seen in Figure 1. All statistical analyses will be
performed by investigators of WP3 (AUMC) in close
collaboration with the Biostatistical Support Group of both
AUMC and University Medical Center Mainz.
The PanCareLIFE Female Fertility Nested
Case-Control Study
The case-control study is nested within the cohort study,
meaning that both cases and controls are selected from
participants of the cohort study. However, only participants
from institutions that are able to provide detailed treatment data
are potential inclusions for the case-control study. This is the
case for participants from 11 out of the 16 cohorts in the cohort
study (Table 1).
The aims of the nested case-control study are to identify specific
treatment-related factors associated with an increased risk of
fertility impairment among CAYA cancer survivors and
investigate possible dose-response relationships between
cumulative dose of radiation from radiotherapy, cumulative
dose of specific anticancer drugs, and the risk of fertility
impairment.
Study Population
The minimal sample size to be included in the nested
case-control study population is calculated a priori. From a
previous study, it was expected that 19% of female childhood
cancer survivors exposed to potentially gonadotoxic treatment
(ie, the exposed group) have low AMH levels compared with
4% among survivors who did not receive such treatment [7].
Based on this information, it is decided to include at least 402
cases and 804 controls (1:2 match), thereby allowing subgroup
analyses including up to 6 subgroups (n=67 cases per subgroup).
This will enable the detection of an odds ratio of 5.63 with a
power of 90% using Fishers’ exact test within the subgroups.
Cases are defined as women who are fertility impaired, as
assessed by the 8 criteria described in Textbox 1; controls are
defined as survivors without fertility impairment (ie, all women
who do not meet any of the 8 criteria). Controls were matched
to cases on the following criteria: country of treatment, age at
time of study assessment (±1 year), calendar year of treatment
(±3 years), and age at first cancer diagnosis (±2 years).
Prior to identifying the cases it is estimated that using these 8
criteria, substantially more than the 402 required cases will be
identified. Therefore, to include the 402 cases that are most
likely to actually be fertility impaired, the decision was made
to hierarchically structure these 8 criteria. Moreover, in making
this hierarchy, we also considered the certainty by which each
criterion can establish whether the remainder of the participants
(ie, the noncases) are actually not fertility impaired (true
controls). Criterion 1 is considered to reflect fertility impairment
with the highest certainty and criterion 8 with the least,
considering the ability of each criterion to also identify “true
controls.” First, women with self-reported (primary or
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secondary) amenorrhea validated by a high FSH and/or a low
AMH level are selected as cases, followed by women with an
established high FSH level together with a low AMH level.
Subsequently, women who reportedly have amenorrhea (primary
or secondary) with no further information on AMH levels are
selected, followed by those with an established low AMH level
while being younger than 30 years and not using any hormones.
Finally, women who indicate by self-report to have ever used
some type of artificial reproductive technique and subsequently
those who have ever tried to become pregnant for at least one
year without success are selected as cases. Ultimately, for the
nested case-control study, each case is identified as a case based
on one criterion only. The process of case accrual ends after
402 cases are selected.
Data Collection
Additional data collected for all selected cases and controls
include type, number of cycles, and cumulative doses of each
chemotherapeutic agent. For radiotherapy data on site,
fractionation schedules and cumulative doses are collected.
Planned Data Analyses
Multivariable regression models will be used to investigate
which risk factors are most strongly associated with an increased
risk of fertility impairment. For this purpose, the associations
with individual chemotherapeutic agents and radiotherapy body
sites and the risk of fertility impairment will be investigated
along with the association with cumulative doses of these
chemo- and radiotherapy body sites.
Results
The PanCareLIFE Female Fertility Cohort Study
The total base cohort consists of 14,379 female 5-year CAYA
cancer survivors, 10,964 of whom are either invited for one of
the local fertility studies in the past (n=8500) or for the
PanCareLIFE female fertility study (n=2464) (Table 1). In total,
data are available from 6619 survivors, either
questionnaire-based only (n=4979), hormonal-based only
(n=72), or both (n=1568), as seen in Figure 1. Of all
questionnaires provided (n=6547), one-quarter (n=1517)
consisted of the standardized PanCareLIFE fertility
questionnaire. Serum AMH levels have been successfully
determined in all 1640 women who provided a blood sample.
FSH levels are available from 1242 women.
Table 2 shows the number of women from all participating
cohorts who potentially meet each of the criteria for fertility
impairment. For some data providers, fertility impairment cannot
be assessed by all 8 criteria because not all necessary
questionnaire or hormonal data are available for their study
population since data were previously collected in local studies.
Table 2. Number of participants in the cohort study who could potentially meet the criteria of fertility impairment by participating cohort.
Criterion 8
(n=5050)
Criterion 7
(n=2759)
Criterion 6
(n=1640)
Criterion 5
(n=5861)
Criterion 4
(n=3133)
Criterion 3
(n=1207)
Criterion 2
(n=1566)
Criterion 1
(n=1455)
Name of study cohort
0110961911091109614615615DCOG LATER cohort
000203203000Hodgkin Lymphoma cohort
24820024820000VIVE cohort
464624464622222Ewing 2008 Clinical Trials cohort
00698383696969Berlin Hormone Analyses cohort
18218218018218285180180Cohort female 5-y cancer survivors Brno
574574301574574198236236Cohort female 5-y cancer survivors Mo-
tole
6850000000Swiss Childhood Cancer Registry cohort
1
113001130000Swiss Childhood Cancer Registry cohort
2
51514651036460Lymphoma survivor cohort
82826582010650Acute lymphoblastic leukemia survivor
cohort
12003512012093535Rhone Alpe cohort 1
006210110106262Rhone Alpe cohort 2
563563122563563109122122Gaslini female survivors cohort
5050445050404242Hematopoietic stem cell transplantation
cohort
10210273102102357272The Edmond and Lily Safra Children’s
Hospital Late Effects cohort
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Table 3. Number of cases and controls identified within study cohorts included in the nested case-control study.
Number of controls matchedCases identified
(n=450)
Study cohortInstitute
Controls identified within
DCOG LATER cohort (n=81)
Controls identified within
same cohort (n=801)
N/Aa238120DCOG LATER cohortDCOG LATER
0158Ewing 2008 Clinical Trials cohortWestfaelische Wilhelms-Univer-
sitaet Muenster
33017Cohort malignant cancer survivors
Brno
Fakultni Nemocinice Brno
19232128Cohort malignant cancer survivors
Motol
Fakultni Nemocnice v Motol
217991Gasline female survivors cohortIstituto Giannina Gaslini
43628Hematopoietic stem cell transplanta-
tion cohort
Great Ormond Street Children’s
Hospital and University College
London Hospital
122418Lymphoma survivor cohort and
Acute lymphoblastic leukemia sur-
vivor cohort
Oslo University Hospital
05628Rhone Alpe cohort 1 and Rhone
Alpe cohort 2
University hospital Saint-Étienne
22112The Edmond and Lily Safra Chil-
dren’s Hospital Late Effects cohort
Edmond and Lily Safra Chil-
dren’s Hospital, Sheba Medical
Center
aN/A: Not applicable.
Results show that within the total group of 6619 participants,
criterion 1 could be evaluated among 21.98% (1455/6619) of
the participants, criterion 2 among 23.66% (1566/6619), criterion
3 among 18.24% (1207/6619), criterion 4 among 47.33%
(3133/6619), criterion 5 among 88.55% (5861/6619), criterion
6 among 24.78% (1640/6619), criterion 7 among 41.68% (2759/
6619), and criterion 8 among 76.30% (5050/6619) of the
participants. However, data providers who collect their data
during the course of PanCareLIFE collect data for all 8 criteria.
This results in a total group of 464 participants for whom all 8
criteria can successfully be evaluated.
All data are collected and entered into local electronic databases
by data providers and sent to the coordinating data center in
Mainz (WP1). These data are subsequently checked, merged,
and cleaned by investigators from WP1 after which a final,
aggregated dataset is sent to the investigators of WP3.
The PanCareLIFE Female Fertility Nested
Case-Control Study
The selection of cases and controls has been successfully
performed using the hierarchically-ordered criteria of fertility
impairment. However, ultimately, it appears that this hierarchy
can be discarded since, after the application of the 8th criterion,
a total of 504 cases have been identified from the total eligible
cohort. Of these, 13 cases are excluded, because no treatment
data are available, and 41 because no appropriate matching
controls can be found. Therefore, ultimately, 450 cases are
included in the case-control study. If the cases identified by the
last criterion (criterion 8) are not included in the nested
case-cohort study, this will lead to fewer than the required 402
cases.
The 450 selected cases are matched to 882 controls. Some cohort
cases cannot be matched to 2 controls owing to an insufficient
number of controls in that cohort. However, because the Dutch
Childhood Oncology Group - Long term Effects after Childhood
Cancer cohort (see Table 1) includes more eligible controls than
required, this cohort was used as a “back-up” control selection
cohort [17]. In total, 9% (81/882) matched controls are selected
from this cohort (Table 3). Overall, 2 matching controls are
found for 432 cases, whereas for 18 cases, only one matching
control could be identified. After the selection of cases and
controls has been finalized, data providers are provided with a
list of survivors in their cohort for whom they have to collect
detailed treatment data.
Data analysis of both the PanCareLIFE cohort study and the
case-control study is currently under way and the first results
are expected to be submitted for publication in 2019.
Discussion
This paper describes the design and methods of 2 studies on
female fertility within the PanCareLIFE project. Due to the large
number of institutions collaborating within this project, these
studies will encompass the largest group of CAYA cancer
survivors among whom female fertility is investigated using
both self-reported and hormonal data. Results will provide
detailed insight into the prevalence of fertility impairment
following CAYA cancer and the diagnostic- or treatment-related
factors associated with an increased risk of fertility impairment.
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This will help clinicians to adequately counsel both girls or
young women who are about to start anticancer treatments as
well as adult female CAYA cancer survivors about issues
concerning their remaining reproductive life span and the
possible need for fertility preservation interventions. Moreover,
knowledge gained from the 2 studies can be incorporated into
existing evidence-based clinical guidelines on female fertility
for CAYA cancer patients and survivors [28,29].
The 2 fertility studies conducted within PanCareLIFE have
several strengths. First, the international collaboration, as
achieved in PanCareLIFE, has resulted in an unprecedented
number of female CAYA cancer survivors for whom data on
fertility impairment are available. Large study populations are
essential to achieve statistically and clinically meaningful results.
Moreover, the large sample size in the PanCareLIFE fertility
studies will allow many subgroup analyses. For these analyses,
survivors whose former treatment is presumed not to negatively
affect fertility (as indicated by the literature available at time
of data analyses) can serve as the reference group when
calculating effect measures, such as relative risks or odds ratios.
Second, within both PanCareLIFE fertility studies, a broad
definition of fertility impairment has been employed using
several criteria that have frequently been used in previous studies
assessing fertility in female CAYA cancer survivors
[11,12,30-33]. By doing so, a large set of data, as provided by
the data providers, who collected their data prior to the
PanCareLIFE project, could be incorporated into the
PanCareLIFE fertility studies. Moreover, using a broad
definition of fertility impairment will enable calculation of an
overall prevalence of fertility impairment and the calculation
of the specific criterion-specific prevalence of fertility
impairment. Each criterion-specific prevalence can then be
compared with those reported in previous studies among CAYA
cancer survivors, which used the same definition (ie, criterion)
for fertility impairment. Third, some criteria of fertility
impairment employed within PanCareLIFE included
self-reported outcomes that are validated by hormonal values.
Attempts to endorse questionnaire-based fertility data by
comparing them with objective hormonal markers is important
because it is known that self-reported fertility data, especially
on menstrual cycle regularities, have limited association with
objective clinical markers [34].
For the cohort study, survivors are considered fertility impaired
when they meet at least one of 8 criteria. For the nested
case-control study, however, a hierarchy is applied to these
criteria, meaning that a survivor is defined as a case based on
the criterion that established fertility impairment with the
presumed highest level of certainty, considering the ability of
this criterion to also identify “true controls” (ie, survivors who
are definitely not fertility impaired based on that criterion by
the end of follow-up). The hierarchy applied to the 8 criteria is
based on several considerations. Criteria 1 through 3 (primary
or secondary amenorrhea combined with a high FSH and/or a
low AMH and high FSH combined with a low AMH) are
deemed strong indicators of fertility impairment because one
marker of (in)fertility (amenorrhea and high FSH, respectively)
is validated by another marker (ie, AMH). AMH is currently
considered the marker of choice when it comes to measuring
ovarian reserve because it seems to be the most stable marker,
it is randomly measurable throughout the menstrual cycle and
it seems to reflect reduced ovarian function early in the sequence
of events leading to menopause [35,36]. Criteria 4 and 5 also
include the outcome amenorrhea; however, in the cases of these
criteria, it is not validated by FSH or AMH values, making them
less certain criteria for fertility impairment because amenorrhea
may also be caused by factors other than ovarian follicle
depletion [37]. Women less than 30 years of age with an AMH
level below <0.5 µg/L (criterion 6) are also considered to be
fertility impaired [38]. However, because hormonal
contraception use has shown to significantly decrease AMH
levels [25], this criterion is evaluated among the nonhormone
users only. The final 2 criteria include self-reported measures
regarding pregnancy attempts (use of artificial reproductive
techniques and unsuccessful pregnancy attempts for at least 12
months, respectively). Both criteria have proven to be good
indicators of sub- or infertility [39,40]. They are, however, at
the bottom of the hierarchy because they only apply to the
subgroup of survivors who have already tried to become
pregnant. Consequently, these criteria do not provide any
information regarding fertility impairment in those who have
not yet attempted to conceive at time of study assessment, as
was true for a substantial portion (approximately two-thirds) of
the included survivor population. By placing criteria 1 through
6 before 7 and 8, the number of women who are categorized as
being fertility impaired based on the criteria that provide
information on fertility impairment in the whole cohort, and not
just in those who have attempted to become pregnant, is
maximized. Moreover, it enables us to easily differentiate
between fertility impairment rates of survivors based on all 8
criteria versus criteria 1 through 6 only.
The fertility studies within PanCareLIFE have some limitations.
First, due to missing information, some of the data on fertility
impairment collected in previous local studies cannot be
successfully recoded to make them compatible with the data
that are collected with the PanCareLIFE questionnaire. As a
consequence, data from some cohorts cannot be considered
when calculating the overall prevalence of fertility impairment.
Second, our studies may be subject to selection bias because
from about 60% of the total invited group of subjects’ outcome
data from are available for the cohort study and even less for
the nested case-control study. This could impact the
generalizability of our study results. To estimate the risk of
selection bias, participants will be compared with
nonparticipants relative to age at time of study assessment and
disease-related characteristics. Third, no information is available
on the fertility outcomes of women treated for CAYA cancer
who died before the study (after having survived for at least 5
years). Because many of these women might have been treated
with relatively high (gonado)toxic treatment regimens, they
would most probably have met at least one of the 8 criteria of
fertility impairment, were they still living. As a consequence,
the risk of fertility impairment calculated based on this study
results might be an underestimation of the “true” risk.
Furthermore, for some (sub)cohorts, not all self-reported or
hormonal data needed to evaluate each of the 8 criteria are
available, because these data were not collected during the local
fertility study in the past. As a result, survivors within certain
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cohorts can be evaluated by one or 2 criteria only.
Hypothetically, these women could also have met one of the
other criteria. However, because data for these other criteria are
lacking, this group of women might be misclassified (ie,
categorized as being not fertility impaired, whereas in reality,
they are), also possibly leading to an underestimation of the
overall prevalence of fertility impairment. For future studies, it
is of high importance that researchers achieve consensus
concerning the assessment of fertility impairment among female
CAYA cancer survivors in late effects studies.
In summary, the 2 fertility studies conducted within
PanCareLIFE will generate evidence-based knowledge
concerning risk factors for impaired fertility among female
CAYA cancer survivors as well as valuable information
regarding differences in the prevalence of fertility impairment
using different criteria to define this impairment. These results
will enhance clinical practice because they will help health care
practitioners provide adequate counseling concerning future
parenthood to CAYA cancer survivors as well as new patients
and refer these individuals to a reproductive specialist for
fertility preservation in a timely manner. The ultimate objective
is to empower patients and survivors and improve their quality
of life.
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Multimedia Appendix 2
Flow of data collected for the two fertility studies within PanCareLIFE project.
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